Someone please explain to sarge CEO's reasoning for pausing the DEPGEM trials, I thought it was a sound considered decision to save ongoing costs and to concentrate assets on getting current three DEP in house drugs phase 2 completed and through to licencing. I also now believe that licencing negotiations are now happening, the CEO was insistent on few occasions that these negotiations are happening now.
DEP-Gemcitabine, page-12
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.8¢ |
Change
-0.002(2.00%) |
Mkt cap ! $40.48M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.7¢ | $37.67K | 384.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.8¢ | 39723 | 3 |
View Market Depth
| Last trade - 12.35pm 03/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |